Tuesday, April 14, 2020

Industry Update and COVID-19 Impact: Join Me for Two Live Video Webinars (May 1 and May 8)

This May, join Dr. Adam J. Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels, for two live video webinars:
  • May 1: Industry Update and COVID-19 Impact: Retail & Specialty Pharmacies (12:00 p.m. to 1:15 p.m. ET)
  • May 8: Industry Update and COVID-19 Impact: PBMs & Payers (12:00 p.m. to 1:15 p.m. ET)
  • Register for both events (May 1 and May 8)

These events are no longer available.

Dr. Fein will help you navigate this challenging time in U.S. drug channels. These 75-minute live events will be broadcast via Zoom from the new Drug Channels Video studio. See details below.

You can sign up for either one of these crucial educational opportunities for only $300 per site per event. We are offering special pricing of $500 if you sign up for both events.

An unlimited number of people may watch at one location. However, we recognize that it may be difficult to gather your team in one location, so we are offering significant discounts for multiple viewing sites. Please contact Paula Fein (paula@drugchannelsinstitute.com) to get special pricing information for 5 or more locations. If you purchase access for multiple sites, we will contact you for the name and email address of a contact person at each location.

Read on for more information about the events.

To help people affected by COVID-19 and the caregivers who are supporting them , DCI will donate 20% of all profits from these events to The Center for Disaster Philanthropy’s COVID-19 Response Fund. This charity has earned a 4-star Charity Navigator rating and is a trusted philanthropic partner of Google, Coca Cola, UPS, Verizon, and many other organizations. The fund supports preparedness, containment, response, and recovery activities for those affected by the coronavirus and for the responders.


We will help you and your team better understand key industry dynamics and how COVID-19 may alter the industry.

Dr. Fein will share DCI’s latest market data and trends from The 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers.

Topics for Industry Update and COVID-19 Impact: Retail & Specialty Pharmacies:
  • The key trends for retail and specialty pharmacy markets
  • The new normal for prescription demand
  • How COVID-19 will change the U.S. payer mix
  • Will the 340B program be disrupted?
  • What’s next for specialty pharmacies
  • The outlook for prescription profits
  • The future for the drugstores’ front-end profits
  • New opportunities for pharmacists as providers
  • My reflections on life in a pandemic world and beyond

Topics for Industry Update and COVID-19 Impact: PBMs & Payers:
  • The key trends for PBMs
  • An update on the latest prescription data
  • What the changing U.S. payer mix means for PBMs and insurers
  • The outlook for benefit design
  • PBMs' role in Managed Medicaid
  • More on the 340B Drug Pricing Program
  • Disruption to the buy-and-bill channel
  • Promise and perils of vertical diversification
  • Further reflections on life in a pandemic world

PLUS: Dr. Fein will take your questions during the event. CLICK HERE to submit questions to Dr. Fein in advance of the events.

  • After you register, you will receive an email with the information you will need to access our live video webinar and add it to your calendar. We will also send you reminder emails one day and one hour before the event.
  • Watch and listen via any device with a web browser (computer, iPad, iPhone/Android, etc.)
  • After each event, you’ll receive a downloadable PDF with the event slides.
  • If your plans change and you can’t make it on May 1 or May 8, we will provide an opportunity to watch a replay of the live video events. Unfortunately, we are unable to offer refunds.
  • Pembroke Consulting clients receive free access to the webinar. Contact Tamra Feldman (admin@drugchannels.net) for details. We will automatically refund payments from anyone at a Pembroke client who purchases access using their corporate email account.

No comments:

Post a Comment